Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.75
Bid: 10.50
Ask: 11.00
Change: 0.75 (7.50%)
Spread: 0.50 (4.762%)
Open: 10.00
High: 10.75
Low: 9.875
Prev. Close: 10.00
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK DIRECTOR DEALINGS SUMMARY: Citrus Buys More easyHotel At Exit Price

Tue, 28th Apr 2020 14:43

(Alliance News) - The follow is a round-up of share dealings by London-listed company directors and managers announced on Monday and Tuesday and not separately reported by Alliance News:

----------

easyHotel PLC - Citrus Holdco Ltd, the investment vehicle of Chair Hermanus Meijer, Non-Executive Director Charles Persello, and Michael Neuman, representative of corporate director Cadim Fonds Inc, buys 183,688 shares at GBP0.70, worth GBP128,582, on Friday last week. At the start of last week, easyHotel offered an exit opportunity to minority shareholders at the same price. Citrus Holdco held 71.2% of the shares at that point, with brand-owner easyGroup having 25.8%, leaving just 3% in public hands. easyHotel plans to cancel its listing on AIM from May 19.

----------

Witan Investment Trust PLC - Non-Executive Director Gabrielle Boyle buys 28,683 shares at 173.41p, worth GBP49,739, on Monday.

----------

Scancell Holdings PLC - Non-Executive Director Martin Diggle sells 2.0 million shares via Vulpes Life Science Fund, at 8p, worth GBP160,000, on Monday and Friday last week. Vulpes now holds 78.5 million shares, a 17% stake.

----------

Manchester & London Investment Trust PLC - Investment Manager Mark Sheppard sells 58,266 shares at GBP5.62 and GBP5.66, worth GBP327,586, on Monday.

----------

Geiger Counter Ltd - Chair George Baird buys 100,000 shares at GBP0.17, worth GBP16,680, on Friday last week.

----------

Alfa Financial Software Holdings PLC - Chief Financial Officer Duncan Magrath buys 100,000 shares at GBP0.79, worth GBP79,000, on Monday.

----------

Artemis Alpha Trust PLC - Fund Manager Kartik Kumar buys 12,500 shares at GBP2.45, worth GBP30,625, on Friday last week.

----------

Jadestone Energy Inc - Non-Executive Chair Dennis McShane buys 150,732 shares at 43.02p to 44.40p, worth GBP65,337, on Friday last week and Monday. Now holds 453,651 shares.

----------

Salt Lake Potash Ltd - Chair Ian Middlemas buys 2.3 million shares, CEO Tony Swiericzuk 505,883, and CFO Shaun Day 102,941 last week, as part of company's placement of 58.8 million shares at AUD0.34 to raise AUD20.0 million. The funds will be used to deliver the Lake Way project in Western Australia. Salt Lake Potash said commissioning is expected to commence in December with first production in the first quarter of 2021.

----------

City Merchants High Yield Trust Ltd - Non-executive directors Tim Scholefield and Stuart McMaster buy 6,000 shares at 171.80p and 25,000 shares at 171.67p, respectively, on Tuesday. The purchases are together worth GBP53,000.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
6 Jun 2014 08:54

Scancell Holdings ImmunoBody technology receives US approval

AIM-listed Pharmaceuticals group Scancell Holdings announced a patent for its DNA ImmunoBody technology has been approved in the US. The patent has been granted by the United States Patent and Trademark Office (USPTO) and covers Scancell's DNA ImmunoBody platform technology. This patent is expect

Read more
6 Jun 2014 08:52

Scancell Granted US Patent For DNA Immunobody Technology

LONDON (Alliance News) - Scancell Holdings PLC said Friday its DNA Immunobody technology platform had been granted a patent by the US Patent and Trademark Office. Scancell said the patent was key for the protection of its pipeline of vaccines utilising the technology. It has already been gr

Read more
2 Jun 2014 11:08

Scancell reports encouraging results of melanoma treatment

Scancell's shares advanced after announcing "encouraging results" from the clinical trial of its SCIB1 ImmunoBody drug for the treatment of stage III/IV melanoma. The phase 1 and 2 trial tested the safety and tolerability of four dose levels of SCIB1 administered intramuscularly using an electropo

Read more
2 Jun 2014 10:39

UK WINNERS & LOSERS: Miners Jump On Upbeat Chinese Data

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Monday.
-------
FTSE 100 - WINNERS
-------
Anglo American, up 1.9%, Rio Tinto, up 1.7%, Glencore, up 1.4

Read more
2 Jun 2014 08:04

Scancell Rises As It Gets More Good Results From Skin Cancer Treatment Trial

LONDON (Alliance News) - Cancer treatment developer Scancell Holdings PLC saw its shares rise Monday after it said the latest results from a trial of its SCIB1 ImmunoBodyÒ treatment on skin cancer had shown further evidence of tumour reduction and disease control, enhanced immune responses and "h

Read more
27 May 2014 12:47

Oxford Technology NAV Declines, Appealing VCT Status Withdrawal

LONDON (Alliance News) - Oxford Technology VCT PLC saw its net asset value per share decline in the year to end-February, and said it was appealing the withdrawal of its venture capital trust status. The trust posted a net asset value per share of 65 pence per share, down from 74 pence in t

Read more
15 May 2014 12:46

Scancell Holdings To Present Phase I/II ImmunoBody Trial Data At ASCO

LONDON (Alliance News) - Scancell Holdings PLC said Thursday that it will announce the latest data from its ongoing Phase I/II clinical trial of its SCIB1 ImmunoBody treatment for stage III/IV melanoma will be presented at the American Society of Clinical Oncology meeting in Chicago at the end of

Read more
1 May 2014 13:03

UK MIDDAY BRIEFING: Lloyds Kicks Off Bank Season With Improvement

LONDON (Alliance News) - Lloyds Banking Group kicked off the first-quarter bank earnings season Thursday, reporting that its pretax profit dropped by a third to GBP1.37 billion after last year was buoyed by gains on the sale of government securities.

However, its un

Read more
1 May 2014 11:27

UK WINNERS & LOSERS: Lloyds Atop FTSE 100 Risers; Weir Leads Fallers

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Thursday.
-------
FTSE 100 - WINNERS
-------
Lloyds Banking Group, up 4.8%. The banking group is the biggest riser in the

Read more
1 May 2014 10:29

Scancell Rises As Long-Time Consultant Joins Its Board

LONDON (Alliance News) - Cancer treatment developer Scancell Holdings PLC saw its shares rise Thursday after it appointed long-time consultant Dr Sally Adams to its board as development director with immediate effect. In a statement, the company, which is developing immunotherapies to treat

Read more
4 Apr 2014 09:55

Scancell To Announce Phase I/II Of Melanoma Clinical Trial On April 8

LONDON (Alliance News) - Scancell Holdings PLC Friday said that it will announce the results of phase one and two of its clinical trial in patients with stage three and four melanoma at the American Association for Cancer Research annual meeting in San Diego next Tuesday. Scancell Holdings

Read more
21 Mar 2014 09:11

Scancell Holdings Completes Phase 1 Of Melanoma Clinical Trial

LONDON (Alliance News) - Scancell Holdings PLC Friday said it has completed patient dosing with 8mg of SCIB1 ImmunoBody in part one of its on-going phase 1/2 clinical trial in patients with Stage III/IV melanoma. The trial followed a study the firm conducted which showed that a 4mg dose of

Read more
18 Feb 2014 09:19

Scancell Says Patent Application For Cancer Fighting Platform Published

LONDON (Alliance News) - Scancell Holdings PLC Tuesday said its patent application for Moditope has been published, with a view to guarding the platform until 2033 once the patent is granted. In a statement, Scancell said the application for the Modicope platform describes how it uses certa

Read more
11 Feb 2014 09:50

Scancell Gets US Orphan Drug Tag For Metastatic Melanoma Treatment

LONDON (Alliance News) - Scancell Holdings PLC said Tuesday its SCIB1 ImmunoBody metastatic melanoma treatment had been granted orphan drug designation by the US Food and Drug Administration. This designation means that Scancell can qualify for a 50% tax credit for clinical trials of the tr

Read more
11 Feb 2014 09:36

CORRECT: UK MORNING BRIEFING: Shares Open Higher But Barclays Down On Results

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.